Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855707 | 0.84 | TSHR (0.36) | TSHRALDH1A1KDM4EHMGCRCHRM1 | |
| SCHEMBL2855633 | 0.84 | TSHR (0.36) | TSHRALDH1A1KDM4EHMGCRCHRM1 | |
| SCHEMBL1965963 | 0.81 | TSHR (0.33) | TSHRALDH1A1KDM4E | |
| SCHEMBL1965967 | 0.81 | TSHR (0.33) | TSHRALDH1A1KDM4E | |
| SCHEMBL3630555 | 0.81 | TSHR (0.33) | TSHRALDH1A1KDM4E | |
| Hydrogen Peroxide SCHEMBL28392769 | 0.81 | TSHR (0.33) | TSHRALDH1A1KDM4E | |
| SCHEMBL15546329 | 0.77 | NR4A1 (0.34) | TSHRKDM4E | |
| SCHEMBL15546331 | 0.77 | NR4A1 (0.34) | TSHRKDM4E | |
| SCHEMBL4629251 | 0.76 | ALDH1A1 (0.45) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL4629249 | 0.76 | ALDH1A1 (0.45) | TSHRALDH1A1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144146-A1 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG | 2011-06-16 | — | — | US | disclosed |
| EP-1809598-B1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-6489322-B1 | BENZOXAZEPINES AS SELECTIVE INHIBITORS OF THE NEURONAL ISOFORM OF NITRIC OXIDE SYNTHASE FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ASTRAZENECA AB (SE) | 2002-12-03 | — | — | US | disclosed |
| EP-0983268-B1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| EP-0983268-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | Astra Aktiebolag (SE) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050382-A1 | AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRA AKTIEBOLAG (SE) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144146-A1 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor | CHRNA3, HCRTR2, CRHR2 | TSHR 72/4885ALDH1A1 2353/4885KDM4E 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.